The global immune checkpoint inhibitors market is anticipated to grow at a significant CAGR during the forecast period. The major factors that are expected to boost the market growth include the growth in demand for suitable therapeutics for the treatment of cancer, favorable reimbursement policies provided by manufacturers & insurance providers in some countries, and a surge in prevalence of cancer across the globe. In addition, growth in the geriatric population and technological advancements in screening & diagnosis of cancer and rising demand for immunotherapy further drive the market growth. Checkpoint inhibitor is a type of drug used in immunotherapy, which helps block the proteins present in tumor cells as they affect the functioning of the immune system.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immune-checkpoint-inhibitors-market
Immune checkpoint inhibitor drugs block different checkpoint proteins including CTLA-4 (cytotoxic T lymphocyte-associated protein 4), PD-1 (programmed cell death protein 1), and PD-L1 (programmed death-ligand 1). Immune checkpoint inhibitor targets checkpoint proteins and assist the immune system to recognize and attack cancer cells. The overall impact of COVID-19 was regarded as negative on the global immune checkpoint inhibitor market, owing to a decline in the number of cancer patients’ visits to hospitals and clinics, which leads to a decline in the demand for Immune checkpoint inhibitors products. For instance, according to NCBI in 2020 around 50% of patient decrease is reported for cancer care in the US, and overall cancer therapies are declined by 50% during COVID-19. Furthermore, the WHO issued guidelines regarding the nonessential planned therapies including cancer and procedures based on the requirement of critical situations. The guidelines suggest providing emergency services to patients who require urgent attention and postponing the therapies and surgery if not urgent, which leads to a decline in the demand for immune checkpoint inhibitors during the COVID-19.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Drug Class
o By Application
- Regions covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape: AstraZeneca plc, Bristol-Myers Squibb Co., and Eli Lilly and Company, among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Immune Checkpoint Inhibitors Market Report by Segment
By Drug Class
- Programmed Death Receptor-1 Inhibitors (PD-1)
- Programmed Death-Ligand 1 Inhibitors (PD-L1)
- CTL-4 Checkpoint Inhibitor
- Indoleamine-2,3-dioxygenase (IDO) Inhibitors
- Lymphocyte-Activation Gene 3 Inhibitors
By Application
- Lung Cancer
- Head and Neck Cancer
- Blood Cancer
- Bladder Cancer
- Skin Cancer
- Colorectal Cancer
- Renal/Kidney Cancer
- Breast Cancer
- Others
A full report of Immune Checkpoint Inhibitors Market is available at: https://www.omrglobal.com/industry-reports/immune-checkpoint-inhibitors-market
Immune Checkpoint Inhibitors Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- AstraZeneca plc
- Bristol-Myers Squibb Co.
- Eli Lilly and Company
